Financials

News Discussions Technicals Forecast Seasonals

Average basic shares outstanding of VYNE Therapeutics Inc.

Annual data

2016

2017

2018

2019

2020

2021

2022

2023

TTM

‪0.00‬

‪‪3.00 M‬‬

‪‪6.00 M‬‬

‪‪9.00 M‬‬

‪‪12.00 M‬‬

Period

Value

Change

Change %

TTM

—

—

—

2023

‪‪10.27 M‬‬

+‪‪7.09 M‬‬

+‪222.44‬%

2022

‪‪3.19 M‬‬

+‪‪327.00 K‬‬

+‪11.44‬%

2021

‪‪2.86 M‬‬

+‪‪1.06 M‬‬

+‪58.74‬%

2020

‪‪1.80 M‬‬

+‪‪1.33 M‬‬

+‪282.06‬%

2019

‪‪471.39 K‬‬

+‪‪170.43 K‬‬

+‪56.63‬%

2018

2017

2016

Quarterly data

Q1 '17

Q2 '17

Q3 '17

Q4 '17

Q1 '18

Q2 '18

Q3 '18

Q4 '18

Q1 '19

Q2 '19

Q3 '19

Q4 '19

Q1 '20

Q2 '20

Q3 '20

Q4 '20

Q1 '21

Q2 '21

Q3 '21

Q4 '21

Q1 '22

Q2 '22

Q3 '22

Q4 '22

Q1 '23

Q2 '23

Q3 '23

Q4 '23

Q1 '24

Q2 '24

Q3 '24

‪0.00‬

‪‪11.00 M‬‬

‪‪22.00 M‬‬

‪‪33.00 M‬‬

‪‪44.00 M‬‬

Period

Value

Change

Change %

Q3 '24

‪‪42.59 M‬‬

+‪‪1.00 K‬‬

‪0.00‬%

Q2 '24

‪‪42.59 M‬‬

+‪‪5.00 K‬‬

+‪0.01‬%

Q1 '24

‪‪42.58 M‬‬

+‪‪11.53 M‬‬

+‪37.14‬%

Q4 '23

‪‪31.05 M‬‬

+‪‪27.77 M‬‬

+‪846.07‬%

Q3 '23

‪‪3.28 M‬‬

+‪‪8.00 K‬‬

+‪0.24‬%

Q2 '23

‪‪3.27 M‬‬

+‪‪19.00 K‬‬

+‪0.58‬%

Q1 '23

‪‪3.25 M‬‬

+‪‪270.02 K‬‬

+‪9.05‬%

Q4 '22

‪‪2.98 M‬‬

‪‪−233.36 K‬‬

‪−7.25‬%

Q3 '22

Q2 '22

Q1 '22

Q4 '21

Q3 '21

Q2 '21

Q1 '21

Q4 '20

Q3 '20

Q2 '20

Q1 '20

Q4 '19

Q3 '19

Q2 '19

Q1 '19

Q4 '18

Q3 '18

Q2 '18

Q1 '18

Q4 '17

Q3 '17

Q2 '17

Q1 '17